Order the Cunningham Panel™
Healthcare Providers
About the Cunningham Panel
The Cunningham Panel™ (Autoimmune Encephalopathy and Basal Ganglia Encephalitis Panel) is a high-complexity blood test that measures the levels of antibodies directed against specific targets in the brain associated with psychiatric and neurologic symptoms, including abnormal movements, seizures, and tics.
The Cunningham Panel™ includes testing for several autoantibodies that may be associated with seizures including anti-dopamine D1, anti-dopamine D2, anti-lysoganglioside GM1, anti-tubulin, and autoantibodies that stimulate calcium/calmodulin-dependent kinase II in human brain cells.
- Developed with over 20 years of research
- Utilized by more than 2,000 clinicians worldwide
- Over 16,000 patients tested
WHY TEST?
Elevated levels of these autoantibodies may indicate that symptoms (such as seizures) are due to an immune-mediated response and require immunomodulatory treatment.
Identifying autoimmune epilepsy is important, as studies have shown that proper treatment can lead to a complete resolution of seizures. In fact, one study found that following immunomodulatory treatment, 81% of patients had “significant improvement in seizure status and 67% achieved seizure freedom, a majority of whom were antiepileptic drug [AED] resistant.” 1
Studies have shown that proper treatment can lead to a complete resolution of seizures.
Ordering the Panel is Easy!
The Cunningham Panel™ of tests requires a clinician order before we can receive and process any specimen. Moleculera Labs can accept authorized clinician test orders from all 50 states in the United States and other countries. (New York patients must have their blood collected outside the State of New York.)
Set-up an account
In our secure online portal and submit your order.
Learn
More
About the Ordering Process and Testing Costs
Understanding Test Results
Fill out the form below to schedule your appointment. Note: This service is open to individual clinicians and group practices only.
- Fang Z, Yang Y, Chen X, Zhang W, Xie Y, Chen Y, Liu Z, Yuan W. Advances in Autoimmune Epilepsy Associated with Antibodies, Their Potential Pathogenic Molecular Mechanisms, and Current Recommended Immunotherapies. Front Immunol. 2017 Apr 25;8:395. doi: 10.3389/fimmu.2017.00395. PMID: 28487693; PMCID: PMC5403900.
- Quek, A. M. L., Britton, J. W., McKeon, A., So, E., Lennon, V. A., Shin, C., Klein, C. J., Watson, R. E., Kotsenas, A. L., Lagerlund, T. D., Cascino, G. D., Worrell, G. A., Wirrell, E. C., Nickels, K. C., Aksamit, A. J., Noe, K. H., & Pittock, S. J. (2012). Autoimmune epilepsy: Clinical characteristics and response to immunotherapy. Archives of neurology, 69(5), 582-593.